xCellSense® delivers live patient-cell drug response, combination synergy, and AI-driven responder insights to improve go/no-go decisions, biomarker strategies, and patient selection.
Request Scientific Consultation
Roughly 90% of oncology candidates fail in the clinic — largely because animal and cell-line models don't predict efficacy. Genomics shows what is present, not what works. xCellSense® tests your asset in live primary cells from blood-cancer patients — the biology those models miss.
This is functional precision medicine aligned with where regulation is heading: the FDA Modernization Act 2.0 (2022) and the FDA's 2025 NAMs Roadmap make primary human-derived, cell-based functional data not just desirable, but expected.
xCellSense® processes a single primary patient sample using an integrated workflow:
Dose-response (IC₅₀, AUC, Eₘₐₓ) for your asset and comparators using the same patient cells — preserved in our proprietary Optimum Media, which maintains primary blood-cancer cell viability where conventional media fail.
Quantitative synergy and antagonism scoring (Bliss, Loewe, ZIP, HSA) to rank regimens — including the sponsor asset ± standard-of-care (SoC) backbones.
Drug effect, antigen density, target engagement, and malignant-vs.-normal selectivity — resolved across blast, stem-cell, differentiated, and immune compartments from the same well. Population resolution where bulk viability only gives an average.
Machine-learning-driven analytics that score synergy, stratify responders from non-responders, and translate complex readouts into a sponsor-ready interpretation — not a raw-data dump.
ML-integrated synergy scoring on live, primary patient cells. Functional, human-relevant evidence — in weeks, not months.
Broad assay menus on cell lines. No heme-oncology specialization, no synergy scoring, months to data.
Propagated models at higher cost and longer timelines, a step removed from the patient.
Describe biology without predicting functional, disease-relevant drug response.
Delivery is governed by defined service-level commitments and quality infrastructure across two accredited labs, with audit-ready documentation throughout.
Services are for Research Use Only (RUO).
SILICON VALLEY
A2LA / ISO 17025
CLIA Certification in Progress
Accredited testing laboratory
SEOUL
KGMP / IVD-certified
Audit-ready quality documentation
IC₅₀, AUC, and Eₘₐₓ plus quantitative synergy matrices (Bliss / Loewe / ZIP / HSA) with regimen ranking.
Antigen density, target engagement, and malignant vs. normal selectivity — resolved across blast, stem-cell, and immune compartments.
Sensitive vs. resistant sample segmentation to generate enrichment and inclusion-criteria hypotheses you can test in the clinic.
Functional drug sensitivity, flow cytometry, and optional NGS in one workflow — genotype and phenotype mapped to measured response.
Interpretation, figures, and the underlying dataset — delivered from sample receipt in weeks, not months.
Human-relevant functional evidence to support the translational sections of development packages.
A scientist will scope a tailored study and return a design and timeline.
